Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BRAXF Stock Summary
In the News
Braxia Scientific reports significant increase in treatment volumes across its clinics
Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has reported a significant increase in treatment volumes across its clinics, which rose by 26.2% in fiscal 2023 to 3,516, compared to 2,785 treatments in the previous year. The company said its growth has been driven by increased demand across all five of its clinics.
Braxia Scientific announces termination of Irwin Naturals merger LOI; retains strategic clinical assets
Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) announced that Irwin Naturals Inc has terminated the non-binding amended and restated letter of intent (LOI) for a business combination between Irwin and Braxia, which the company called “disappointing”. The medical research and telemedicine firm, however, said it remains committed to evaluating a number of potential strategic opportunities to create shareholder value in the mental health industry, which continues to evolve and consolidate.
Braxia Scientific reports 50.5% increase in 3Q revenue; updates on acquisition by Irwin Naturals
Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has reported third-quarter results that show a sharp rise in revenue as the company increased its in-clinic ketamine treatments and continued to expand its US telemedicine platform, KetaMD. The medical research and telemedicine company also updated investors on its proposed acquisition by Irwin Naturals Inc. (CSE:IWIN) after the two companies entered into a non-binding Letter of Intent (LOI) in January.
Braxia Scientific closes first tranche of its non-brokered offering for aggregate proceeds of $751,218.83
Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) said it has closed the first tranche of its previously announced non-brokered offering resulting in the issuance of 13,658,524 units of the company at a price of 5.5 cents per unit for aggregate proceeds of $751,218.83. The company said it intends to use the net proceeds of the LIFE offering and the concurrent placement to support the rollout of its telemedicine platform in the United States, for clinic expansion in Canada and to continue intellectual property development, and the company expects to use the net proceeds of the concurrent placement for working capital and general corporate purposes.
Braxia Scientific announces up to $1.5M offering and concurrent private placement
Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has announced an offering of up to 27,272,727 units of the company at a price of $0.055 each for aggregate proceeds of up to $1.5 million pursuant to the listed issuer financing exemption (LIFE) and a concurrent private placement of up to 7,272,727 units for aggregate gross proceeds of up to $400,000. The net proceeds of the LIFE offering will be used to support the rollout of the company's telemedicine platform in the United States, for clinic expansion in Canada, and to continue intellectual property development, Braxia said.
Irwin Naturals announces LOI to acquire Braxia Scientific to create new market leader
Irwin Naturals Inc. (CSE:IWIN) said it has entered into a non-binding amended and restated Letter of Intent (LOI) for a business combination with Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) in a move it said will create a new market leader in North American mental health. The company noted that Braxia Scientific is a medical research and telemedicine company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.
Irwin Naturals an Braxia Scientific partner to accelerate in-human development of new therapies for mental health
Irwin Naturals Inc. (CSE:IWIN) and Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) have signed a Letter of Intent (LOI) entering into a partnership to launch Clinical Research Services across Irwin's growing US-based network of clinics, Emergence. Under the LOI, Irwin will invest up to $2 million over the next 12 months to launch initial research services beginning with at least five clinics in Florida.
Braxia Scientific sees Q2 revenue increase, with in-clinic treatment up 34.5%
Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has announced an increase in revenues for its second quarter and the first half ended September 30, 2022, with in-clinic treatment rising by 34.5% as it continues to build on its core strengths and priorities. The company also said it also evaluating strategic capital market opportunities to create shareholder value.
Braxia Scientific says telemedicine provider KetaMD ramps up Florida operations in wake of Hurricane Ian
Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has announced the expansion of its ketamine therapy program to help Floridians cope with mental health, including those affected by Hurricane Ian. Braxia's wholly-owned KetaMD subsidiary provides at-home ketamine treatments for Florida residents suffering from depression and related mental health conditions through telemedicine and a mobile app.
Braxia Scientific launches KetaMD as first Florida patients complete initial virtual ketamine treatments at home
Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) said it has successfully launched KetaMD in the US state of Florida, adding new patients and completing initial ketamine treatments. Eligible patients, as determined by one of KetaMD's licensed Florida healthcare practitioners, received medically supervised treatments, guided virtually by registered nurses with mental health expertise, while in the comfort of their homes, according to Braxia.
BRAXF Financial details
BRAXF Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
Metric | History | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0.01 | 0.01 | 0.01 | |
Net income per share | 0 | -0.56 | -0.07 | -0.06 | |
Operating cash flow per share | -0.01 | -0.03 | -0.03 | -0.03 | |
Free cash flow per share | -0.01 | -0.03 | -0.03 | -0.04 | |
Cash per share | 0.02 | 0.07 | 0.05 | 0.01 | |
Book value per share | 0.03 | 0.1 | 0.05 | 0.01 | |
Tangible book value per share | 0.03 | 0.06 | 0.04 | 0 | |
Share holders equity per share | 0.03 | 0.1 | 0.05 | 0.01 | |
Interest debt per share | 0 | 0 | 0 | 0 | |
Market cap | 22.94M | 75.15M | 10.52M | 5.9M | |
Enterprise value | 22.08M | 64.1M | 2.01M | 4.59M | |
P/E ratio | -132.81 | -0.85 | -0.87 | -0.45 | |
Price to sales ratio | 108.2K | 74.52 | 7.08 | 3.13 | |
POCF ratio | -79.42 | -14.86 | -2.33 | -0.8 | |
PFCF ratio | -65.76 | -14.8 | -2.32 | -0.71 | |
P/B Ratio | 20.72 | 4.73 | 1.17 | 3.68 | |
PTB ratio | 20.72 | 4.73 | 1.17 | 3.68 | |
EV to sales | 104.17K | 63.57 | 1.35 | 2.44 | |
Enterprise value over EBITDA | -129.6 | -6.02 | -0.28 | -0.67 | |
EV to operating cash flow | -76.46 | -12.68 | -0.44 | -0.62 | |
EV to free cash flow | -63.31 | -12.62 | -0.44 | -0.55 | |
Earnings yield | -0.01 | -1.18 | -1.15 | -2.23 | |
Free cash flow yield | -0.02 | -0.07 | -0.43 | -1.41 | |
Debt to equity | 0 | 0.01 | 0.02 | 0.13 | |
Debt to assets | 0 | 0.01 | 0.02 | 0.05 | |
Net debt to EBITDA | 5.02 | 1.04 | 1.19 | 0.19 | |
Current ratio | 19.57 | 4.47 | 3.81 | 1 | |
Interest coverage | 0 | -5.24K | -1.45K | -416.51 | |
Income quality | 1.67 | 0.06 | 0.37 | 0.56 | |
Dividend Yield | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 322.06 | 6.13 | 4.35 | 2.9 | |
Research and developement to revenue | 235.85 | 1.96 | 0.13 | 0.05 | |
Intangibles to total assets | 0 | 0.38 | 0.15 | 0.22 | |
Capex to operating cash flow | 0.21 | 0 | 0.01 | 0.12 | |
Capex to revenue | -283.02 | -0.02 | -0.02 | -0.48 | |
Capex to depreciation | -28.97 | -1.11 | -1.09 | -1.6 | |
Stock based compensation to revenue | 15.18K | 3.07 | 1.63 | 0.46 | |
Graham number | 0.05 | 1.13 | 0.28 | 0.1 | |
ROIC | -0.16 | -0.67 | -0.77 | -3.89 | |
Return on tangible assets | -0.15 | -7.76 | -1.23 | -4.36 | |
Graham Net | 0.02 | 0.05 | 0.04 | 0 | |
Working capital | 989.28K | 8.84M | 7.12M | 7.56K | |
Tangible asset value | 1.11M | 8.85M | 7.19M | 736.67K | |
Net current asset value | 989.28K | 8.8M | 6.99M | -123.75K | |
Invested capital | 0 | 0.01 | 0.02 | 0.13 | |
Average receivables | 0 | 56.72K | 462.23K | 609.97K | |
Average payables | 0 | 1M | 1.32M | 875.89K | |
Average inventory | 0 | 16.89K | 0.5 | 4.34K | |
Days sales outstanding | 0 | 41.06 | 199.05 | 79.22 | |
Days payables outstanding | 1.26K | 184.94 | 50.55 | 75.18 | |
Days of inventory on hand | 1.35K | 0 | 0 | 0.6 | |
Receivables turnover | 0 | 8.89 | 1.83 | 4.61 | |
Payables turnover | 0.29 | 1.97 | 7.22 | 4.86 | |
Inventory turnover | 0.27 | 3.9M | 0 | 610.7 | |
ROE | -0.16 | -5.59 | -1.35 | -8.19 | |
Capex per share | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.01 | -0.03 | 0 | 0 | 0 | |
Operating cash flow per share | -0.02 | 0 | 0 | 0 | 0 | |
Free cash flow per share | -0.02 | -0.01 | 0 | 0 | 0 | |
Cash per share | 0.01 | 0.01 | 0 | 0 | 0 | |
Book value per share | 0.03 | 0.01 | 0 | 0 | 0 | |
Tangible book value per share | 0.01 | 0 | 0 | 0 | 0 | |
Share holders equity per share | 0.03 | 0.01 | 0 | 0 | 0 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 6.03M | 6.81M | 6.28M | 3.61M | 1.5M | |
Enterprise value | 4.69M | 5.5M | 5.51M | 3.44M | 1.9M | |
P/E ratio | -0.69 | -0.22 | -1.96 | -3.3 | -0.41 | |
Price to sales ratio | 12.33 | 13.04 | 10.46 | 6.07 | 3.05 | |
POCF ratio | -1.64 | -5.17 | -11.11 | -25.48 | -2.82 | |
PFCF ratio | -1.66 | -5.05 | -11.08 | -25.48 | -2.77 | |
P/B Ratio | 0.76 | 4.24 | 7.81 | 6.74 | -4.1 | |
PTB ratio | 0.76 | 4.24 | 7.81 | 6.74 | -4.1 | |
EV to sales | 9.6 | 10.53 | 9.18 | 5.8 | 3.86 | |
Enterprise value over EBITDA | -2.1 | -2.59 | -7.51 | -18.48 | -2.43 | |
EV to operating cash flow | -1.27 | -4.17 | -9.75 | -24.33 | -3.57 | |
EV to free cash flow | -1.29 | -4.08 | -9.72 | -24.33 | -3.51 | |
Earnings yield | -0.36 | -1.12 | -0.13 | -0.08 | -0.6 | |
Free cash flow yield | -0.6 | -0.2 | -0.09 | -0.04 | -0.36 | |
Debt to equity | 0.03 | 0.13 | 0.18 | 1.13 | -1.6 | |
Debt to assets | 0.02 | 0.05 | 0.05 | 0.21 | 0.25 | |
Net debt to EBITDA | 0.6 | 0.62 | 1.05 | 0.88 | -0.51 | |
Current ratio | 1.54 | 1 | 0.58 | 0.48 | 0.18 | |
Interest coverage | 0 | -738.87 | -187.89 | -10.03 | -33.39 | |
Income quality | 1.7 | 0.17 | 0.7 | 0.52 | 0.59 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 3.27 | 3.4 | 0.75 | 0.3 | 1.27 | |
Research and developement to revenue | 0.16 | 0 | 0.03 | 0 | 0 | |
Intangibles to total assets | 0.69 | 0.22 | 0.32 | 0.3 | 0.37 | |
Capex to operating cash flow | -0.01 | 0.02 | 0 | 0 | 0.02 | |
Capex to revenue | 0.11 | -0.06 | 0 | 0 | -0.02 | |
Capex to depreciation | 0.28 | -0.2 | -0.03 | 0 | -0.12 | |
Stock based compensation to revenue | 0.31 | 0.21 | 0.01 | 0.01 | 0.01 | |
Graham number | 0.08 | 0.06 | 0.01 | 0.01 | 0.01 | |
ROIC | -0.29 | -1.19 | -0.78 | -0.16 | -1.31 | |
Return on tangible assets | -0.74 | -2.54 | -0.44 | -0.13 | -0.62 | |
Graham Net | 0 | 0 | 0 | -0.01 | -0.01 | |
Working capital | 715.82K | 7.56K | -752.78K | -961.21K | -1.81M | |
Tangible asset value | 1.48M | 736.67K | -64.17K | -332.9K | -1.23M | |
Net current asset value | 580.6K | -123.75K | -879.63K | -1.48M | -2.31M | |
Invested capital | 0.03 | 0.13 | 0.18 | 1.13 | -1.6 | |
Average receivables | 198.94K | 312.75K | 245.46K | 76.75K | 81.26K | |
Average payables | 635.7K | 867.55K | 1.18M | 1.31M | 1.4M | |
Average inventory | 44.68K | 9.03K | 4.34K | 0 | 0 | |
Days sales outstanding | 39.86 | 70.45 | 12.3 | 10.83 | 16.64 | |
Days payables outstanding | 40.42 | 64.29 | 154.89 | 205.84 | 158.94 | |
Days of inventory on hand | 0.59 | 0.51 | 0 | 0 | 0 | |
Receivables turnover | 2.26 | 1.28 | 7.32 | 8.31 | 5.41 | |
Payables turnover | 2.23 | 1.4 | 0.58 | 0.44 | 0.57 | |
Inventory turnover | 152.78 | 176.08 | 6302031.28B | 0 | 0 | |
ROE | -0.27 | -4.77 | -1 | -0.51 | 2.48 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
BRAXF Frequently Asked Questions
What is Braxia Scientific Corp. stock symbol ?
Braxia Scientific Corp. is a CA stock , located in Mississauga of On and trading under the symbol BRAXF
What is Braxia Scientific Corp. stock quote today ?
Braxia Scientific Corp. stock price is $0.0064 today.
Is Braxia Scientific Corp. stock public?
Yes, Braxia Scientific Corp. is a publicly traded company.